BioLume™ delivery
Ionisable lipid nanoparticles with tissue-tropic surface ligands that dock onto target cells first. Four generations of chemistry, all manufactured on the same line.
12× selectivity−40°C stable
Series B closed — $92M to fund four clinical programs
Genetic medicine, switched on at the source.
GeneLink Bio engineers programmable RNA therapeutics with tissue-level precision. Our BioLume™ delivery platform switches gene editors on only where the disease lives — and switches them off again before they do harm.
9Programs
3In the clinic
41Patents
94%In-vivo edit rate
BioLume™ LNP · v4
Live model
0.02% off-target
12× tissue selectivity
1 dose durability
Technology platform
One engine for delivery.
One for the edit itself.
Most genetic medicines fail on two physics problems: getting to the right cell, and stopping once the job is done. We built a platform around both — then licensed the result back into our own pipeline.
PrecisionEdit™ editors
Engineered base and prime editors refined by deep mutational scanning. Ninety-four percent in-vivo edit rates with off-target activity held at assay floor.
94.2% in vivo0.02% off-target
ProteoFold AI
A closed design loop over a 40-million-variant library: our models propose editor and lipid variants, the wet lab scores them, and the scoring goes straight back in.
40M variants18 days design cycle
SignalOff™ control
A small-molecule switch that gates editor activity. Dose it to dial editing up, withhold it and the editor is inert — the safety property regulators actually ask about.
Reversible on/off<6h clearance
Design, make, measure — then design again.
Our platform exists to shorten the loop between a hypothesis and a dataset. Structural biology, lipid chemistry, ML-guided design and in-house GLP toxicology all sit in the same building, so a redesign takes weeks rather than quarters.
- In-house GLP toxicology — IND-enabling packages delivered in 14 weeks, not 14 months.
- One manufacturing line — all four delivery generations run on the same process, so scale-up is a parameter change.
- Redundant safety layers — tissue tropism, the SignalOff™ switch and a dose cap, each independently validated.
118Scientists
34Publications
6Pharma partners
Research pipeline
Nine programs.
Four in the clinic by 2028.
Every program below derives from the same platform, which is the point: our second asset cost a fraction of the first, and our fourth cost a fraction of the second.
| Program | Phase progress | Next milestone | Status |
|---|---|---|---|
GLB-101
Hypertrophic cardiomyopathy
MYBPC3 · cardiac muscle
|
Interim 24-week dataQ2 2027 · EMA PRIME granted | Lead asset | |
GLB-118
Familial hypercholesterolaemia
LDLR · hepatic
|
Single-ascending-dose readoutQ4 2026 · FDA Fast Track | Partnering | |
GLB-204
Duchenne muscular dystrophy
DMD exon 51 · skeletal muscle
|
First patient dosedQ1 2027 · multi-ascending dose | Clinical | |
GLB-330
Solid tumours
KRAS G12D · tumour microenvironment
|
IND submissionH1 2027 · oral + IV formulation | Partnering | |
GLB-402
Amyotrophic lateral sclerosis
C9orf72 · CNS
|
GLP toxicology startQ3 2026 · intrathecal route | Preclinical | |
GLB-512
Chronic pain, non-opioid
SCN9A · dorsal root ganglia
|
Development candidate nomination2027 · 2 lead series | Discovery |
No programs match this filter.
How a GeneLink program moves.
- 01 · Target validation — human genetics first. We only pursue targets with causal human evidence, never animal-only signals.
- 02 · Editor + lipid pairing — the payload and the particle are designed together, because a perfect editor in the wrong cell is a toxicity signal.
- 03 · NHP proof of durability — non-human primate data with single-dose durability beyond 12 months before any IND is filed.
- 04 · First-in-human under the switch — every clinical protocol starts with the SignalOff™ control enabled by design.
Leadership
The people holding the pipette.
A team that has taken genetic medicines from first-in-human through approval — and who have lived through the delivery problems that stop most of them.
Dr. Aisha Rahmani
Co-founder · Chief Executive OfficerLed three rare-disease programs to approval. Built the CMC strategy behind the industry's first room-temperature LNP.
Dr. Martin Klee
Co-founder · Chief Scientific OfficerAuthor of the base-editor lineage our editors descend from. 60+ papers on genome-editing specificity.
Dr. Sofia Marchetti
Chief Technology Officer · PlatformBuilt the four-generation lipid library and the ProteoFold design loop. Previously led mRNA formulation at scale.
Dr. Rafael Mendes
Chief Medical OfficerCardiologist and gene-therapy trialist. Ran the first-in-human studies for two cardiac gene programs.
Scientific & clinical advisory board
Fourteen advisors across structural biology, cardiology, neurology and regulatory science.
Prof. Helena VossKarolinska Institute · structural biology
Dr. Kenji NakamuraKyoto University · prime editing
Dr. Priya BalanBroad Institute · computational design
Prof. Elias FrankMIT · lipid biophysics
Dr. Nour Haddadex-EMA · regulatory strategy
Publications
Peer-reviewed, not press-released.
Thirty-four papers, 11,400 citations and the usual caveat: a platform is only as credible as the reproducibility of the work behind it.
Tissue-selective lipid nanoparticles enable hepatocyte-restricted base editing in non-human primates
A reversible small-molecule switch gives dose-controlled in-vivo gene editing
Deep mutational scanning maps the specificity landscape of engineered Cas variants
Prime editing restores MYBPC3 function in human cardiomyocytes and murine models
Machine-learned lipid design expands the extrahepatic delivery landscape
Durable LDL-cholesterol reduction after a single dose of a liver-tropic editor in preclinical models
Investor relations
Backing the programmable-medicine decade.
Series B closed in March 2026 at $92M, led by an existing institutional syndicate with two strategic investors participating. Proceeds fund GLB-101 through interim Phase 2 data and carry GLB-118 into dose expansion.
$92MSeries B, March 2026
3.2 yrsCash runway at current burn
$1.8BPeak sales potential, lead asset
14 grantedOf 41 filed patent families
Investor relationsir@genelinkbio.com
Headquarters185 Binney Street, Cambridge, MA 02142
European siteHochbergerstrasse 60, 4057 Basel
Data roomAvailable under NDA on request